Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy. Combining the KRAS G12C inhibitor sotorasib with panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, may be an effective strategy. METHODS: G12C who had not received previous treatment with a KRAS G12C inhibitor to receive sotorasib at a dose of 960 mg once daily plus panitumumab (53 patients), sotorasib at a dose of 240 mg once daily plus panitumumab (53 patients), or the investigator's choice of trifluridine-tipiracil or regorafenib (standard care; 54 patients). The primary end point was progression-free survival as assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Key secondary end points were overall survival and objective response. RESULTS: After a median follow-up of 7.8 months (range, 0.1 to 13.9), the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 6.3) and 3.9 months (95% CI, 3.7 to 5.8) in the 960-mg sotorasib-panitumumab and 240-mg sotorasib-panitumumab groups, respectively, as compared with 2.2 months (95% CI, 1.9 to 3.9) in the standard-care group. The hazard ratio for disease progression or death in the 960-mg sotorasib-panitumumab group as compared with the standard-care group was 0.49 (95% CI, 0.30 to 0.80; P = 0.006), and the hazard ratio in the 240-mg sotorasib-panitumumab group was 0.58 (95% CI, 0.36 to 0.93; P = 0.03). Overall survival data are maturing. The objective response was 26.4% (95% CI, 15.3 to 40.3), 5.7% (95% CI, 1.2 to 15.7), and 0% (95% CI, 0.0 to 6.6) in the 960-mg sotorasib-panitumumab, 240-mg sotorasib-panitumumab, and standard-care groups, respectively. Treatment-related adverse events of grade 3 or higher occurred in 35.8%, 30.2%, and 43.1% of patients, respectively. Skin-related toxic effects and hypomagnesemia were the most common adverse events observed with sotorasib-panitumumab. CONCLUSIONS: In this phase 3 trial of a KRAS G12C inhibitor plus an EGFR inhibitor in patients with chemorefractory metastatic colorectal cancer, both doses of sotorasib in combination with panitumumab resulted in longer progression-free survival than standard treatment. Toxic effects were as expected for either agent alone and resulted in few discontinuations of treatment. (Funded by Amgen; CodeBreaK 300 ClinicalTrials.gov number, NCT05198934.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, KRAS G12C (glycine to cysteine) can be targeted using the covalent inhibitors, such as sotorasib, in combination with EGFR antagonists, such as panitumumab [75].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [75]
In the citing paper
“While KRAS and EGFR dual targeting holds promise in KRAS-mutant CRC, responses are often short-lived; most patients relapse within months due to acquired resistance.”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [6]
In the citing paper
“While dual KRAS and epidermal growth factor receptor (EGFR) inhibition shows promise in treating KRAS-mutant colorectal cancer (CRC), resistance remains a major challenge.”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [6]
In the citing paper
“the phase 3 CodeBreaK 300 trial comparing sotorasib at two doses (960 mg or 240 mg) plus panitumumab with investigator's choice of trifluridine/tipiracil or regorafenib in patients with chemotherapy-refractory KRAS G12C-mutated metastatic colorectal cancer was ongoing, and has shown improved progression-free survival with this combination strategy at both the doses tested. 19”
From Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial (2024) · cites this paper as [19]
In the citing paper
“Clinical studies of other KRAS G12C inhibitors, such as sotorasib and adagrasib, support this hypothesis, with higher response rates observed when used in combination with an EGFR inhibitor compared to when used as single-agent treatment in patients with CRC16–20.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [17]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Self-citationSotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationRandomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02088 · Cited by 569
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
Cited by
Items 101–200 of 381
Milsap, A., Tsai, J., Jafry, B. H., Kim, A. C., Kazmi, S. M. A., & Verma, N. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00975-w · Cited by 11
Shi, Y., Ba, Y., Wang, J., Xiong, J., Gu, K., Chen, Y., Zheng, Z., Wang, Z., Guo, W., Cheng, Y., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02229-4 · Cited by 12
“28 Given that cetuximab β shares an identical amino acid sequence with cetuximab, it will present a promising future in the therapeutic landscape of mCRC. Compared with the phase 1 study and the phase 3 study of cetuximab β for second-line treatment of mCRC, 14 – 16 , no new or unexpected safety…”
Chemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation
Likasitwatanakul, P., Li, Z., Doan, K. T., Spisák, S., Raghawan, A. K., Liu, Q., Liow, P., Lee, S., Chen, D. J., Bala, P., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.07.003 · Cited by 12
Boccaccino, A., Cassaniti, M., Rossini, D., Faccani, L., Casadio, C., & Tamberi, S. (2025) · Cancers · doi:10.3390/cancers17203336 · Cited by 13
“In the subgroup analyses, the survival benefit was preserved among older patients ( ≥ 65 years) with both sotorasib dosages [141,142].”
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
Jin, Y., He, X., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00361-9 · Cited by 15
“In targeted therapy, studies on KRAS G12C-mutated colo-rectal cancer have demonstrated significant efficacy of Sotorasib (AMG 510) as a monotherapy, while combining it with anti-EGFR agents like Panitumumab is being explored to address resistance and improve outcomes [445–447].”
KRAS Inhibition in Pancreatic Ductal Adenocarcinoma
Pradeep, R., Isbeih, N. J., Abraham, F. F., Noori, E., Yeung, Z. P., & Kundranda, M. N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020873 · Cited by 9
New options for late-line treatment of metastatic colorectal cancer
Lonardi, S., & Pietrantonio, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00881-1 · Cited by 8
Self-citationWahoski, C. C., & Singh, B. (2024) · Cancers · doi:10.3390/cancers16132472 · Cited by 9
“Adagrasib and sotorasib are KRAS G12C inhibitors that show an increased effect when used in combination with cetuximab or panitumumab, respectively [34,35].”
BackgroundPolo-like Kinase 1 Inhibition in KRAS -Mutated Metastatic Colorectal Cancer
Stebbing, J., & Bullock, A. J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0251 · Cited by 7
Cherri, S., Libertini, M., Noventa, S., Oneda, E., Meriggi, F. A., & Zaniboni, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062522 · Cited by 9
“This study included 53 patients with advanced CRC with KRAS G12C mutation refractory to chemotherapy [28].”
Self-citationAdagrasib in the treatment of colorectal cancer
Haddad, S. F., Bouferraa, Y., & Nair, K. G. (2025) · Future Oncology · doi:10.1080/14796694.2025.2524311 · Cited by 10
“The phase III CodeBreaK 300 trial evaluated the efficacy of sotorasib and panitumumab, an anti-EGFR monoclonal antibody, versus the investigator’s choice standard of care therapy (SOC) with trifluridine – tipiracil or regorafenib in previously treated KRAS G12C -mutated mCRC [33].”
InfluentialBaird, L., Zhang, L., Hidaka, T., Xi, L., Wang, K., Tateno, K., Iso, T., Suzuki, T., Kumada, K., Katsuoka, F., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03162-7 · Cited by 10
“In a recent phase 3 clinical trial in which Sotorasib was co-administered with the EGFR inhibitor Panitumumab, the clinical response was signi fi cantly better for patients who received the higher dose of 960 mg, compared to the lower dose of 240 mg, per day of Sotorasib [68].”
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
Tang, D., Kroemer, G., & Kang, R. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000946 · Cited by 16
Lee, S., Kim, J., Kim, H.-G., Hwang, S., Kim, K., Lee, J. H., Seo, J., Kang, M.-S., Jung, E. H., Suh, K. J., et al. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.016 · Cited by 8
“For instance, although somatic mutations in KRAS , NRAS , BRAF , and ERBB2 genes are known prognostic factors in the targeted therapy era [4-7], the small sample size of our study limited us from determining whether these mutations act as prognostic factors in survival analysis.”
BackgroundÖzgü, E., Kaplan, B. G., Sivakumar, S., Sokol, E. S., Aydın, E., Tokat, Ü. M., Adibi, A., Karakoç, E. G., Hu, J., Kurzrock, R., et al. (2024) · BJC Reports · doi:10.1038/s44276-024-00086-2 · Cited by 11
Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
Novoplansky, O., Jagadeeshan, S., Prasad, M., Yegodayev, K. M., Marripati, D., Shareb, R. A., Greenshpan, Y., Mathukkada, S., Lulu, T. B., Bhattacharya, B., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03227-0 · Cited by 8
Mahadevan, K. K., Maldonado, A. S., Li, B., Bickert, A. A., Perdyan, A., Kumbhar, S. V., Piya, S., Sockwell, A. M., Morse, S. J., Arian, K. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.28.640711 · Cited by 7
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
Signorelli, C., Calegari, M. A., Anghelone, A., Passardi, A., Frassineti, G. L., Bittoni, A., Lucchetti, J., Angotti, L., Giacomo, E. D., Zurlo, I. V., et al. (2024) · Current Oncology · doi:10.3390/curroncol31120574 · Cited by 6
Ito, M., Miyata, Y., Hirano, S., Morihara, N., Takemoto, M., Irisuna, F., Kushitani, K., Suda, K., Soh, J., Takeshima, Y., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02187-y · Cited by 7
“Combination treatment for tumors harboring KRAS G12C is a promising approach and is not limited to lung cancer [23, 24].”
Meng, X., Lu, Z., Fu, M., Sha, S., & Li, T. (2025) · Discover Oncology · doi:10.1007/s12672-025-02632-x · Cited by 7
Kavgacı, G., Akiva, İ., Ozon, Y. H., Berkil, H., Karadayi, H., Dizdar, O., & Yalçın, Ş. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70042 · Cited by 11
“Recent clinical trials have demonstrated promising outcomes with KRAS G12C inhibitors (e.g., sotorasib and adagrasib) alone or in combination with anti-EGFR therapy, suggesting a paradigm shift in the treatment of these patients [30,31].”
Pan‐ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer
Buchloh, J., Spitzner, M., Zimmermann, H., Fang, X., Contreras, C. T., Schneider, C., de Oliveria, T., Küffer, S., Linnebacher, M., Rühlmann, F., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70086 · Cited by 6
Clinical Actionability of Genes in Gastrointestinal Tumors
Gonzalez, N. S., Patelli, G., & Crisafulli, G. (2025) · Genes · doi:10.3390/genes16101130 · Cited by 7
“In mCRC, the Code-BreaK 300 phase III trial compared sotorasib plus panitumumab versus investigator’s choice chemotherapy (regorafenib, or TAS-102) in refractory KRAS p.G12C-mutant mCRC, demonstrating improved progression-free survival and objective response rate with OS data still immature [156].”
Luan, W.-Y., Zhao, Q., Zhang, Z., Xu, Z.-X., Lin, S.-X., & Miao, Y. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i10.110661 · Cited by 9
Mulero‐Sánchez, A., Bosma, A. R., Visuvasam, B., Pouliopoulou, N., van de Ven, M., Proost, N., Boeije, M., Lieftink, C., Beijersbergen, R. L., Bernards, R., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03616-z · Cited by 8
“For instance, in KRAS-G12C-mutant colorectal cancer, the FDA has approved the use of KRAS-G12C inhibitors in combination with EGFR-targeting antibodies (adagrasib plus cetuximab or sotora-sib plus panitumumab), illustrating the clinical potential of rationally designed combinations [24, 25].”
Metabolic reprogramming in colorectal cancer: Mechanisms and therapeutic insights
Xiao, W., Tan, D., Zeng, W., Nie, X., & Wang, M. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102054 · Cited by 8
Focus on RAS Codon 61 Mutations in Metastatic Colorectal Cancer: A Retrospective Analysis
Schietroma, F., Anghelone, A., Valente, G., Beccia, V., Caira, G., Spring, A., Trovato, G., Bello, A. D., Ceccarelli, A., Chiofalo, L., et al. (2024) · Cancers · doi:10.3390/cancers16050988 · Cited by 5
“Finally, the phase III CodeBreaK 300 trial showed that dual KRAS G12C and EGFR blockade with sotorasib and panitumumab in refractory RAS G12C-mutated mCRCs is associated with longer progression-free survival and a higher response rate than the standard treatment [45].”
BackgroundSelf-citationAgnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution
Алексахина, С. Н., Ivantsov, A. O., & Имянитов, Е. Н. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074094 · Cited by 8
“Similarly to BRAF V600 inhibitors, these drugs appear to be more efficacious for colorectal cancer when administered in combination with anti-EGFR antibodies [101,102].”
BackgroundGonzalez, N. S., Marchese, P. V., Baraibar, I., Ros, J., Salvà, F., Rodríguez, M., Salvà, C., Vaghi, C., Alcaráz, A., García, A., et al. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2349287 · Cited by 9
“The data for OS are evolving [59].”
Ding, Y., Su, H., Shu, Y., & Chen, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30437 · Cited by 6
Ugai, S., Yao, Q., Takashima, Y., Zhong, Y., Matsuda, K., Kawamura, H., Imamura, Y., Okadome, K., Mima, K., Arima, K., et al. (2024) · Cancer Science · doi:10.1111/cas.16262 · Cited by 9
“Polymerase chain reaction (PCR) and pyrosequencing were used to detect mutations in KRAS (codons 12, 13, 61, and 146), 19,20 BRAF (codon 600), and PIK3CA (exons 9 and 20) 21 as previously described.”
BackgroundMethodMolecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations
Yasin, F., Sokol, E. S., Vasan, N., Pavlick, D. C., Huang, R. S. P., Pelletier, M., Levy, M. A., Pusztai, L., Lacy, J., Zhang, J. Y., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae259 · Cited by 11
Akkuş, E., Öksüz, N. E., & Erul, E. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104741 · Cited by 5
Österlund, E., Ristimaki, A. P., Nunes, L., Kytölä, S. I., Aho, S., Heervä, E., Uutela, A., Lehtomäki, K., Stedt, H., Halonen, P., et al. (2025) · BJC Reports · doi:10.1038/s44276-025-00188-5 · Cited by 5
“These have ef fi cacy in mCRC when combined with EGFR inhibitors [22, 23].”
Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How?
Barsch, M., Dopfer, E.-P., Schultheis, A. M., & Quante, M. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01397-y · Cited by 8
Tan, D., Li, G., Li, X., Zhai, W., & Jing, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1734653 · Cited by 9
“Despite advances in conventional treatments such as surgery, chemotherapy, and radiotherapy, patients with advanced CRC often experience poor survival and frequent disease recurrence (Morris et al., 2023; Fakih et al., 2023).”
Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here
May, M. S., Park, W., & O'Reilly, E. M. (2026) · Drugs · doi:10.1007/s40265-026-02295-0 · Cited by 7
Lin, Q., Morales-Giron, A. A., Sander, C., Curtis, J. M., Barnes, H., Patel, P. S., de la Cruz, F. F., Riedl, J. M., Matsubara, H., Nakamura, H., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1788 · Cited by 10
“9, 11, 14–17).”
Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries
Shouki, B., Abdelsalam, A., Abdullah, A. S., Alshammari, K. M., Ahmed, A. M., Dawoud, E., Heinemann, V., Mohamed, A., Chehal, A. A., Mohammed, A., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241299324 · Cited by 6
“Alternatively, the panel acknowledges several options, including sotorasib + panitumumab, adagrasib + cetuximab, and trifluridine/tip-iracil + bevacizumab, as supported by studies such as CodeBreak 300, 36 KRYSTAL-1, 37 and SUNLIGHT, 38 respectively ( A = 100%).”
Pan-Cancer Molecular Biomarkers: Practical Considerations for the Surgical Pathologist
Jafari, P., Forrest, M. E., Segal, J. P., Wang, P., & Tjota, M. Y. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100752 · Cited by 9
Kazmi, F., Shrestha, N., Liu, T. F. D., Foord, T. H., Heesen, P., Booth, S. W., Dodwell, D. J., Lord, S., Yeoh, K., & Blagden, S. P. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014872.pub2 · Cited by 17
Aroldi, F., Élez, E., André, T., Perkins, G., Prenen, H., Popovici, V. C., Gallagher, P. F., Houlden, J., Collins, L., Roberts, C., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14068-1 · Cited by 5
“…adagrasib (MRTX849)] that covalently bind to the cysteine of the glycine-12-cysteine (G12 C) substitution of KRASG12 MT, reported in 2–4% of mCRC [46], in combination with EGFR monoclonal antibodies (CodeBreaK300 [47]; KRYSTAL-1 [48] have shown promising results in heavily pre-treated CRC patients.”
KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
Xiao, A., & Fakih, M. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.05.004 · Cited by 7
Self-citationPrecision medicine in the treatment of colorectal cancer with liver metastases
Xu, Y., Lv, Y., Zhu, Z., Chen, Y., Zhou, P., Ye, L., Tang, W., & Xu, J. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0483 · Cited by 6
“…300 trial, the median progression-free survival was 5.6 months, 3.9 months, and 2.2 months in the 960-mg sotorasib-panitumumab, 240-mg sotorasib-panitumumab, and trifluridine-tipiracil or regorafenib groups, respectively; moreover, the objective response was 26.4%, 5.7%, and 0%, respectively 9 .”
BackgroundInfluentialRojas, M., Manzi, M., Madurga, S., Velásquez, F. E. G., Romero, M. A., Marín, S., Cascante, M., & Maurel, J. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002337 · Cited by 8
Wei, X., Blaj, C., Al-Radhawi, M. A., Lai, L., Maldonato, B. J., Yang, Y. C., Seu, L., Gundlapalli, H., Jiang, L., Ayala, M. A. M., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1616 · Cited by 9
Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics
Grochot, R. M., Bartolini, M., Algaze, S. D., Reimann, P., Winder, T., Lenz, H., & Fontana, E. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-516576 · Cited by 5
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies
Vanclooster, P., Seghers, S., & Prenen, H. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001042 · Cited by 5
Cardona, P., & Houk, B. E. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1501 · Cited by 4
Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions
Zhu, G., Pei, L., Ye, D., Tang, Q., Xu, H., & Bi, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189382 · Cited by 7
Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer
Jayachandran, P., Elliott, A., Soni, S., Battaglin, F., Mittal, P., Algaze, S. D., Lo, J. H., Yang, Y., Ashouri, K., Torres, E. T. R., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03484-z · Cited by 6
“The median PFS was 5.6 months in the 960-mg sotorasib – panitumumab group compared with 2.2 months in the standard-care group [30].”
InfluentialHuo, L., Yue, H., Yang, R., Sun, X., Wang, Z., Liu, H., Liu, J., Feng, R., & Liang, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643133 · Cited by 5
Revolutionizing KRAS p.G12C therapy in metastatic colorectal cancer: The triumph of dual inhibition
Ottaiano, A., & Santorsola, M. (2023) · Med · doi:10.1016/j.medj.2023.11.005 · Cited by 4
Cutshaw, G., Joshi, N., Wen, X., Quam, E., Bogatcheva, G. T., Hassan, N. A., Uthaman, S., Waite, J. R., Sarkar, S., Singh, B., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202410919 · Cited by 6
Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis
Dang, S., Zhang, S., Zhao, J., & Li, W. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03449-8 · Cited by 9
“…in another phase 3 RCT study that chemorefrac-tory metastatic CRC patients with KRAS G12C mutation were randomly assigned in a 1:1:1 ratio to receive sotora-sib (960 mg once daily) plus panitumumab, sotorasib (240 mg once daily) plus panitumumab, and the investigator’s choice of SOC [28].”
MethodResultMatteucci, L., Sullo, F. G., Gallio, C., Esposito, L., Muratore, M., Rapposelli, I. G., Calistri, D., Petracci, E., Rengucci, C., Capelli, L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011071 · Cited by 5
“More recently, specific RAS mutations such as KRAS G12C have gained interest as possible actionable targets, following the evaluation of sotorasib or adagrasib in combination with anti-EGFR [4,5].”
BackgroundInfluentialPesola, G., Epistolio, S., Cefalì, M., Trevisi, E., Dosso, S. D., & Frattini, M. (2024) · Cancers · doi:10.3390/cancers16233923 · Cited by 6
Adorisio, R., Ciardiello, D., Rappa, A., Gervaso, L., Pelizzari, G., Marinucci, L., Fusco, N., Zampino, M. G., Fazio, N., Venetis, K., et al. (2024) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.11.007 · Cited by 5
Guo, H., Miao, L., & Yu, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177219 · Cited by 6
Molecular features and clinical actionability of gene fusions in colorectal cancer
Sullo, F. G., Garinet, S., Blons, H., Taïeb, J., Laurent‐Puig, P., & Gallois, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104656 · Cited by 5
Self-citationSayed, M. S., Idrissi, Y. A., Ahmed, O., Samir, S., Pandita, S., Saeed, F. U., Elraggal, D., Abdulazeem, H. M., & Saeed, A. (2025) · Medical Oncology · doi:10.1007/s12032-025-02684-7 · Cited by 5
“When sotorasib was combined with panitumumab, the incidence of AEs increased markedly, with 94.3% of patients in the higher-dose group experiencing side effects [13].”
InfluentialAfrăsânie, V. A., Marinca, M. V., Gafton, B., Rusu, A., Froicu, E.-M., Sur, D. G., Lungulescu, C. V., Popa, R. C., Afrăsânie, I., Ivanov, A. V., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1557609 · Cited by 6
Kavgacı, G., Dızdar, Ö., & Yalçın, Ş. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001587 · Cited by 5
“This enhancement has been observed in clinical studies of sotorasib with panitumumab and adagrasib with cetuximab [6,7].”
BackgroundConcurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRCPreprint
Alonso, S., Chu, K., Parsons, M. J., Granowsky, E., Gunasinghe, H. I., Shia, J., Yaeger, R. D., & Dow, L. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.05.668666 · Cited by 4
Cardona, P., Strydom, N., & Houk, B. E. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1489 · Cited by 3
Global alliances in translational cancer research
Luo, H., Lu, Y., Shitara, K., Lenz, H.-J., & Xu, R.-H. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.005 · Cited by 3
Kasper, S., & Sebastian, M. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0002 · Cited by 4
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma
Entrialgo‐Cadierno, R., Morali, K., Feliu, I., Wang, Y., Evans, J., Yáñez-Bartolomé, M., López, I., Macaya, I., Cueto‐Ureña, C., Sin-Coscujuela, D., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.03.020 · Cited by 8
EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers
Han, J., Yu, B., Jing, J., He, X., Hua, Y., & Xu, G. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01075-4 · Cited by 6
“…antibody cetuximab for KRAS G12C colorectal cancer in 2024, and sotorasib with EGFR-targeting monoclonal antibody panitumumab for KRAS G12C metastatic colorectal cancer in 2025, giving the promising clinical activities when combining KRAS G12C inhibitors with EGFR blockade [30, 31, 33, 35, 36].”
InfluentialAbdollahi, A., Favata, M. F., Weber, M., Roman, V. D., Hess, R., Hammond, K., Farren, M. R., Schaffer, M., Gilmartin, A. G., Wang, H., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0327588 · Cited by 4
Ding, C., Yao, R., Wang, Y., Liu, H., Li, C., & Xie, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1656372 · Cited by 7
Ianniello, M., Ottaiano, A., Bocchetti, M., Ruggiero, R., Santorsola, M., Sirica, R., Caraglia, F., Ceccarelli, A., Toscano, E., Picone, C., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07273-w · Cited by 3
Li, J., Wang, Z., Huang, J., Ba, Y., Cao, B., Luo, S., Li, W., Bai, C., Song, Z., Xiong, J., et al. (2026) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(25)00267-5 · Cited by 3
Shen, T., Fei, W., Hu, Z., Pang, M., Ma, J., Zhou, T., & Shang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109345 · Cited by 4
Eslinger, C. R., Sonbol, M. B., George, B., Babiker, H., Borad, M. J., & Bekaii‐Saab, T. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s559325 · Cited by 6
“55 These allele-specific and vertical inhibition strategies provide a rational framework for enhancing efficacy, delaying resistance, and expanding the therapeutic potential of KRAS -directed therapy (Table 2).”
Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond
Misirian, A., Pai, J., & Hanna, D. L. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261432058 · Cited by 4
Lou, E., Xiu, J., Baca, Y., Saeed, A., Prakash, A., Gholami, S., Subramanian, S., Starr, T. K., Fontana, E., Pandey, R., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200786 · Cited by 6
“17 Examples have emerged over the past several years that inhibition of KRAS MT (e.g., G12C) induces changes in the surrounding TIME that sensitize tumors to checkpoint inhibitor therapy.”
BackgroundSotorasib in KRAS -Mutated Colorectal Cancer
Fakih, M. G., & Chao, J. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2406109 · Cited by 4
Self-citationPan, Z., Qian, Y., Wang, Y., Zhang, T.-S., Song, X., Ding, H., Li, R., Zhang, Y., Wang, Z., Wang, H., et al. (2025) · Cancer Science · doi:10.1111/cas.70017 · Cited by 5
Voutsadakis, I. A. (2025) · Pharmacogenomics · doi:10.1080/14622416.2025.2479414 · Cited by 4
KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications
Emami, A., Sharif, P. M., & Rezaei, N. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2500426 · Cited by 4
“Another combination approach with EGFR inhibitors involves panitumumab, further supporting the notion that resistance to AMG 510 in CRC cells is linked to the overactivation of RTKs (particularly EGFR) [123,124].”
Improving the Dosing Schedules of Targeted Anticancer Agents
Levêque, D. (2025) · Pharmaceuticals · doi:10.3390/ph18060848 · Cited by 4
“The median progression-free survival (primary endpoint) was slightly superior with the 960 mg dosage (5.6 months versus 3.9 months with 240 mg) but again with similar drug exposures [78].”
InfluentialYokoi, R., Mori, T., Hirosawa, K. M., Kondo, R., Taguchi, T., Matsuhashi, N., & Suzuki, K. G. N. (2025) · iScience · doi:10.1016/j.isci.2025.113374 · Cited by 4
Agnostic drug development revisited
Hernando‐Calvo, A., Rossi, A., Vieito, M., Voest, E. E., & Garralda, E. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102747 · Cited by 4
Choi, D.-H., Jang, H., Lim, S. H., Kim, S. T., Hong, J. Y., Park, S. H., Park, J. O., Kim, D. G., Kim, K., & Lee, J. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155473 · Cited by 3
Moretto, R., Rossini, D., Murgioni, S., Ciracì, P., Nasca, V., Germani, M. M., Calegari, M. A., Vetere, G., Intini, R., Taravella, A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00329 · Cited by 5
“Data about RAS (codons 12, 13, 59, 61, 117, and 146 of KRAS and NRAS ) and BRAF (Val600Glu mut) mutational status were collected at baseline by local assessment of the primary tumor or related metastases.”
Self-citationINDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases
Patel, S., Seshadri, R. A., Saklani, A. P., Somashekhar, S. P., Rohit Kumar, C., Singh, S., Sukumar, V., & Bhatt, A. (2024) · JCO Global Oncology · doi:10.1200/go-24-00306 · Cited by 4
Ghosh, S., Fan, F., Powell, R. T., Park, Y. S., STEPHAN, C. C., Kopetz, S., Ellis, L. M., & Bhattacharya, R. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241303302 · Cited by 4
“16 Combination therapies involving sotorasib with panitumumab, 17 and adagrasib with cetuximab 18 have demonstrated moderate improvements over single agent G12C inhibitors in patients with mCRC.”
Jacob, J., Anami, Y., High, P. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.20.581056 · Cited by 3
Breaking barriers: the latest insights into KRAS G12C inhibitors
Attieh, F., & Kourié, H. R. (2024) · Future Oncology · doi:10.1080/14796694.2024.2394009 · Cited by 3
A new era with advanced immunotherapy
Lopez, C. B., Ruijgrok, E. J., & van Eijck, C. H. J. (2024) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-24-37 · Cited by 2
“Notably, a phase I study has reported on a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and mismatch repair deficiency (MMR)- proficient metastatic CRC (NCT04117087) (19).”
InfluentialKRAS inhibitors in drug resistance and potential for combination therapy
Rathod, L. S., Sakle, N. S., & Mokale, S. N. (2024) · Tumori Journal · doi:10.1177/03008916241289206 · Cited by 3
Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges
Yang, X., Li, X., Zhang, Y., Zhang, S., Zhang, M., Sun, C., Yang, L., Liu, H., & Yuan, S. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2444865 · Cited by 4
Parente, P., Grillo, F., Callegarin, M., Luchini, C., Milione, M., Mattiolo, P., Gafà, R., Pagni, F., Malapelle, U., Macciomei, M. C., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.001 · Cited by 3
The Development of Novel Treatment Strategies for Rhabdomyosarcoma
Nakano, K. (2026) · Cancers · doi:10.3390/cancers18040690 · Cited by 2
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer
Sahin, I. H., Xiu, J., Baca, Y., Khushman, M. M., Grothey, A. F., Palumbo, E., Rahman, S., Weinberg, B. A., Goel, S., Akce, M., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01329-w · Cited by 2
Systematic and precise interventions for KRAS-mutant cancers
Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 4
“In KRAS G12C - mutant CRC, the combination of KRAS G12C inhibition with EGFR-targeted therapy has improved response rates and progression-free survival compared with historical controls, underscoring the importance of simultaneously addressing upstream feedback in this lineage [204].”
InfluentialPastor, P. G., Gonzalez, N. S., Salvà, F., Ros, J., Baraibar, I., Rodríguez-Castells, M., de Torres, C. S., García, A., Alcaráz, A., Vaghi, C., et al. (2026) · Genes · doi:10.3390/genes17040460 · Cited by 4
Zhao, Q., Li, S., Chen, A., Zhu, S., Zhong, J., Zhang, P., She, Y.-L., Chen, R., Liu, W., & Wang, Y. (2026) · Clinical Epigenetics · doi:10.1186/s13148-026-02144-7 · Cited by 2
“The inconspicuous clinical presentation and overgrowth feature of CRC account for the occurrence of metastasis at the time of initial diagnosis, resulting in the ever-growing incidence and mortality rate of CRC patients [2, 3].”
Metadata
- Authors
- Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., Meriggi, F., Cunningham, D., Yeh, K.-H., Chan, E., Chao, J., Saportas, Y., Tran, Q., Cremolini, C., & Pietrantonio, F.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte (M.G.F.), and Amgen, Thousand Oaks (E.C., J.C., Y.S., Q.T.) — both in California; Oncologia Medica, Università Cattolica del Sacro Cuore, and Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome (L.S.), the Oncology Department, Fondazione Poliambulanza Istituto Ospedaliero, Brescia (F.M.), the Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa (C.C.), and the Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan (F.P.) — all in Italy; the Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka (T.E.), and the Experimental Therapeutics and GI Oncology Department, National Cancer Center Hospital East, Kashiwa (Y.K.) — both in Japan; the Medicine Department of Hemato...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-07
- Volume
- 389
- Issue
- 23
- Pages
- 2125-2139
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387859726
- Semantic Scholar
- 775955729cc149c0cdcaed25ee8100657413b921
- Cited by
- 398
- References
- 37
- Citations by year
- 2026: 127 · 2025: 143 · 2024: 121 · 2023: 7
- FWCI
- 48.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- Amgen (NA)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- sotorasib, panitumumab, KRAS G12C mutation, metastatic colorectal cancer, EGFR inhibition, KRAS G12C inhibitors, combination therapy, progression-free survival, overall survival, objective response, trifluridine/tipiracil, regorafenib, dose comparison, refractory cancer, targeted therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Panitumumab, Immune Checkpoint Inhibitors, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Mutation, Phenylurea Compounds, Piperazines, Pyridines, Pyrimidines, Pyrrolidines, Thymine, Trifluridine, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.